The Study
Cytochrome P450 1B1 directs pathogenic Th17 cell generation and autoimmune disease by fine-tuning redox homeostasis and mitochondrial integrity.
This study saw that a certain protein (CYP1B1) was more common in sick mice and people with gut problems, and it seemed to be linked to some immune cells acting up. But they didn’t test if changing the protein actually caused the sickness — so we can’t say it’s the reason.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
A protein called CYP1B1 makes certain immune cells (Th17) become harmful and cause gut inflammation and cancer. It does this by messing up the cell's energy and antioxidant system.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 520 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — blocking this protein could help treat autoimmune gut diseases like colitis by stopping the bad immune cells without affecting good ones.
- 2When CYP1B1 is missing, harmful immune cells die because they build up too much ROS and their mitochondria break.
- 3Giving them glutathione or an antioxidant fixes this and lets them survive.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Proceedings of the National Academy of Sciences of the United States of America
Year
2026
Authors
Wen Hu, Yunqing Sun, Jie Sun, Yue Liang, Suoqin Jin, Jing Liu, Bing Wu
Related Content
Claims (5)
Under specific environmental and nutritional conditions, the human body can restore normal physiological function in chronic autoimmune conditions through its inherent regenerative processes.
When the CYP1B1 gene is not functional, pathogenic Th17 cells experience a drop in glutathione synthetase, which leads to higher levels of reactive oxygen species and impaired mitochondrial function.
When CYP1B1 is absent, increasing glutathione or removing reactive oxygen species leads to improved mitochondrial function and increased survival and production of pathogenic Th17 cells.
In people and mice with colitis, the enzyme Cytochrome P450 1B1 is present at higher levels in the colon, and this increase is linked to more severe inflammatory bowel disease and a higher risk of colorectal cancer through the activity of pathogenic Th17 cells.
The enzyme Cytochrome P450 1B1 increases the development and harmful activity of a specific type of immune cell called pathogenic Th17 cells in colitis, but does not affect the formation of nonpathogenic Th17 cells.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.